Abstract:Engineering immune cells to express chimeric antigen receptors (CARs) allows the recognition of specific tumor-associated antigens, enhancing the immune cells' potential for identification and elimination of tumor cells. In glioblastoma (GBM), the most common and aggressive primary central nervous system (CNS) tumor in adults, standard treatment—which includes maximal surgical resection followed by cycles of chemotherapy and radiotherapy—often leads to recurrence, with an average survival of about 15 months. This happens partly due to the presence of glioblastoma stem cells (GSCs), which are resistant to conventional treatments and possess tumor-initiating properties, highlighting the need for targeted therapies. CAR technology has been applied to various cell types, but Natural Killer (NK) cells, in particular, offer unique advantages, such as feasibility for allogeneic transplants and reduced cytotoxicity risks. Preclinical and some clinical studies have shown that CAR-NK cells can efficiently eliminate target cells with minimal side effects, though few studies have focused on GBM. Given the need for improvement in GBM therapy, we developed a third-generation CAR receptor adapted for expression in NK cells, incorporating two antigen-binding domains specific to selected GSC markers associated with GSC maintenance and tumorigenic potential. We evaluated the cytotoxic potential of CAR-NK cells vs. Mock-NK cells (control) against GBM cell lines through co-culture assays. After in silico analysis for relevant GSC markers, we verified antigen expression in GBM cell lines (A172, LN18, U87-MG, U138-MG, U251-MG, U343-MG) by flow cytometry (FC) and immunocytochemistry (ICC), in both tumor cell monolayer and tumor spheres. CAR-NK cells were produced by transducing NK-92 cells with a lentiviral vector carrying the CAR construct. Efficiency was confirmed via FC, neomycin selection, and RT-qPCR. CAR-NK and Mock-NK cells were co-cultured with ZsGreen+ U251-MG cells, and cytotoxicity was assessed using LDH release assays and fluorescence microscopy (FM). Results showed that the selected antigens were expressed in all six GBM cell lines, with increased expression in tumor spheres indicating their relevance as GSC markers. CAR-NK cells demonstrated superior cytotoxicity compared to Mock-NK cells, as indicated by higher death rates in LDH assays and greater fluorescence reduction detected by FM after co-cultivation with ZsGreen+ U251-MG. In conclusion, the selected GSC antigens are promising targets for designing CARs against GBM cells. The CAR-NK cells exhibited superior cytotoxic activity compared to Mock-NK cells, suggesting effective targeting of GBM cells. Further in vivo experiments are underway to confirm these findings and evaluate CAR-NK cell activity for potential clinical applications. Citation Format: Vitoria A Lima, Thiago G Mitsugi, Oswaldo K Okamoto. Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B034.

KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells

Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma

Abstract 3313: iPSC-derived natural killer cells expressing EGFR-CAR against glioblastoma

PD1CD28 chimeric molecule enhances EGFRvIII specific CAR-T cells in xenograft experiments in mouse models

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES

Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell

[Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19]

Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models.

Immu-67. Intracranial Il12 Secreting Car-T Cells Obviate The Need For Lymphodepletion And Combat Heterogeneity Via Microglial Interactions

PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

Abstract B034: Assessing the cytotoxic potential of novel CAR-NK cells targeting glioblastoma stem cell antigens

Abstract 4006: IL12-secreting CAR-T cells eliminate the requirement for lymphodepletion and promote epitope spreading via local antigen presenting cells

Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses